Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Piedad

Internal Medicine Colorado Springs, CO Medical Doctor

NPI 1295732493 CMS profile 194318

2920 N Cascade Ave, Ste 201, Colorado Springs, CO 80907

Open in the dashboard

General payments

$154,200

854 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Piedad of Colorado Springs, CO is reported in the CMS Open Payments database as having received $154,200 across 854 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,779 159
2024 General $66,281 175
2023 General $35,838 164
2022 General $13,104 89
2021 General $2,889 92
2020 General $3,848 95
2019 General $1,463 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Piedad
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Samuel Piedad were reported at $30,779. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Samuel Piedad Internal Medicine median Middle half National median
2019 $1,463 $159 $48–$570 $163
2020 $3,848 $119 $33–$402 $114
2021 $2,889 $135 $37–$521 $132
2022 $13,104 $141 $42–$496 $149
2023 $35,838 $149 $45–$519 $160
2024 $66,281 $154 $47–$537 $164
2025 $30,779 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $93,048 210 payments
  2. Horizon Therapeutics plc $34,179 83 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $8,786 30 payments
  4. Otsuka America Pharmaceutical, Inc. $6,905 45 payments
  5. AstraZeneca Pharmaceuticals LP $1,490 44 payments
  6. Novo Nordisk Inc $1,218 62 payments
  7. Mallinckrodt Hospital Products Inc. $948 27 payments
  8. Daiichi Sankyo Inc. $614 27 payments
  9. Novartis Pharmaceuticals Corporation $557 20 payments
  10. ANI Pharmaceuticals, Inc. $556 35 payments
  11. Other $5,900 271 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $79,774 48 payments
  2. Honoraria $27,810 13 payments
  3. Food and Beverage $19,006 696 payments
  4. Travel and Lodging $17,068 80 payments
  5. Consulting Fee $10,089 4 payments
  6. Education $453 13 payments
Products named General payments · program years 2019–2025
  1. KRYSTEXXA Inflammation/Rare Disease $83,085 172 payments
  2. KRYSTEXXA Krystexxa $34,153 82 payments
  3. Kerendia $8,786 30 payments
  4. JYNARQUE $6,186 28 payments
  5. Ozempic $800 42 payments
  6. ACTHAR $670 23 payments
  7. RYBELSUS $644 35 payments
  8. XARELTO $486 32 payments
  9. ELIQUIS $449 24 payments
  10. INJECTAFER $425 16 payments
  11. Other $9,452 421 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

2,280

Median for Internal Medicine: 777

Drug cost

$157,113

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kerendia Finerenone Brand 22 $32,039
Eliquis Apixaban Brand 31 $24,984
Januvia Sitagliptin Phosphate Brand 21 $17,569
Xarelto Rivaroxaban Brand 13 $14,531
Spiriva Respimat Tiotropium Bromide Brand 26 $13,658
Vascepa Icosapent Ethyl Brand 21 $10,564
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 21 $10,183
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 23 $3,210
Sodium Chloride 0.9 % Sodium Chloride Brand 70 $2,558
Esomeprazole Magnesium Generic 15 $2,266

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$86,262

Medicare's payments for the services billed

Medicare patients

308

Average age 76

Services billed

1,154

158 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 54%
Diabetes 46%
Ischemic heart disease 41%
Heart failure 35%
Depression 35%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $55,223
$55,223 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $241
$241 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $201
$201 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $175
$175 — —
UBRELVY
  • AbbVie, Inc. $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

854 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record